Economic Evaluation of Azacitidine in Elderly Patients with Acute Myeloid Leukemia with High Blast Counts

BACKGROUND: Azacitidine is an hypomethylating agent widely adopted for the treatment of acute myeloid leukaemia (AML) in patients who are ineligible for curative-intent chemotherapy. Patients with low bone marrow blast counts (< 30%) experience improved survival with azacitidine, but the benefits...

Descripción completa

Detalles Bibliográficos
Autores principales: Coyle, D., Villeneuve, Pierre J. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7248154/
https://www.ncbi.nlm.nih.gov/pubmed/31562614
http://dx.doi.org/10.1007/s41669-019-00180-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7248154/
https://www.ncbi.nlm.nih.gov/pubmed/31562614
http://dx.doi.org/10.1007/s41669-019-00180-z

Ejemplares similares